Sahar F. Bannoura , Amro Aboukameel , Husain Yar Khan , Md Hafiz Uddin , Hyejeong Jang , Eliza W Beal , Amalraj Thangasamy , Yang Shi , Seongho Kim , Kay-Uwe Wagner , Rafic Beydoun , Bassel F. El-Rayes , Philip A. Philip , Ramzi M. Mohammad , Muhammad Wasif Saif , Mohammed Najeeb Al-Hallak , Boris C. Pasche , Asfar S. Azmi
{"title":"RCC1 通过 Ran GTPase 对亚细胞蛋白定位的调控驱动胰腺导管腺癌生长","authors":"Sahar F. Bannoura , Amro Aboukameel , Husain Yar Khan , Md Hafiz Uddin , Hyejeong Jang , Eliza W Beal , Amalraj Thangasamy , Yang Shi , Seongho Kim , Kay-Uwe Wagner , Rafic Beydoun , Bassel F. El-Rayes , Philip A. Philip , Ramzi M. Mohammad , Muhammad Wasif Saif , Mohammed Najeeb Al-Hallak , Boris C. Pasche , Asfar S. Azmi","doi":"10.1016/j.canlet.2024.217275","DOIUrl":null,"url":null,"abstract":"<div><div>Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy, with limited therapeutic options. Here, we evaluated the role of regulator of chromosome condensation 1 (<em>RCC1</em>) in PDAC. RCC1 functions as a guanine exchange factor for GTP-binding nuclear protein Ran (Ran) GTPase and is involved in nucleocytoplasmic transport. <em>RCC1</em> RNA expression is elevated in PDAC tissues compared to normal pancreatic tissues and correlates with poor prognosis. <em>RCC1</em> silencing by RNAi and CRISPR-Cas9 knockout (KO) results in reduced proliferation in 2-D and 3-D cell cultures. <em>RCC1</em> knockdown (KD) reduced migration and clonogenicity, enhanced apoptosis, and altered cell cycle progression in human PDAC and murine cells from LSL-Kras<sup>G12D/+</sup>; LSL-Trp53<sup>R172H/+</sup>; Pdx1-Cre (KPC) tumors. Mechanistically, <em>RCC1</em> KO shows widespread transcriptomic alterations including regulation of PTK7, a co-receptor of the Wnt signaling pathway. <em>RCC1</em> KD disrupted subcellular Ran localization and the Ran gradient. Nuclear and cytosolic proteomics revealed altered subcellular proteome localization in <em>Rcc1</em> KD KPC-tumor-derived cells and several altered metabolic biosynthesis pathways. In vivo, <em>RCC1</em> KO cells show reduced tumor growth potential when injected as sub-cutaneous xenografts. Finally, <em>RCC1</em> KD sensitized PDAC cells to gemcitabine chemotherapy treatment. This study reveals the role of <em>RCC1</em> in pancreatic cancer as a novel molecular vulnerability that could be exploited to enhance therapeutic response.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"604 ","pages":"Article 217275"},"PeriodicalIF":9.1000,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth\",\"authors\":\"Sahar F. Bannoura , Amro Aboukameel , Husain Yar Khan , Md Hafiz Uddin , Hyejeong Jang , Eliza W Beal , Amalraj Thangasamy , Yang Shi , Seongho Kim , Kay-Uwe Wagner , Rafic Beydoun , Bassel F. El-Rayes , Philip A. Philip , Ramzi M. Mohammad , Muhammad Wasif Saif , Mohammed Najeeb Al-Hallak , Boris C. Pasche , Asfar S. Azmi\",\"doi\":\"10.1016/j.canlet.2024.217275\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy, with limited therapeutic options. Here, we evaluated the role of regulator of chromosome condensation 1 (<em>RCC1</em>) in PDAC. RCC1 functions as a guanine exchange factor for GTP-binding nuclear protein Ran (Ran) GTPase and is involved in nucleocytoplasmic transport. <em>RCC1</em> RNA expression is elevated in PDAC tissues compared to normal pancreatic tissues and correlates with poor prognosis. <em>RCC1</em> silencing by RNAi and CRISPR-Cas9 knockout (KO) results in reduced proliferation in 2-D and 3-D cell cultures. <em>RCC1</em> knockdown (KD) reduced migration and clonogenicity, enhanced apoptosis, and altered cell cycle progression in human PDAC and murine cells from LSL-Kras<sup>G12D/+</sup>; LSL-Trp53<sup>R172H/+</sup>; Pdx1-Cre (KPC) tumors. Mechanistically, <em>RCC1</em> KO shows widespread transcriptomic alterations including regulation of PTK7, a co-receptor of the Wnt signaling pathway. <em>RCC1</em> KD disrupted subcellular Ran localization and the Ran gradient. Nuclear and cytosolic proteomics revealed altered subcellular proteome localization in <em>Rcc1</em> KD KPC-tumor-derived cells and several altered metabolic biosynthesis pathways. In vivo, <em>RCC1</em> KO cells show reduced tumor growth potential when injected as sub-cutaneous xenografts. Finally, <em>RCC1</em> KD sensitized PDAC cells to gemcitabine chemotherapy treatment. This study reveals the role of <em>RCC1</em> in pancreatic cancer as a novel molecular vulnerability that could be exploited to enhance therapeutic response.</div></div>\",\"PeriodicalId\":9506,\"journal\":{\"name\":\"Cancer letters\",\"volume\":\"604 \",\"pages\":\"Article 217275\"},\"PeriodicalIF\":9.1000,\"publicationDate\":\"2024-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer letters\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0304383524006700\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0304383524006700","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy, with limited therapeutic options. Here, we evaluated the role of regulator of chromosome condensation 1 (RCC1) in PDAC. RCC1 functions as a guanine exchange factor for GTP-binding nuclear protein Ran (Ran) GTPase and is involved in nucleocytoplasmic transport. RCC1 RNA expression is elevated in PDAC tissues compared to normal pancreatic tissues and correlates with poor prognosis. RCC1 silencing by RNAi and CRISPR-Cas9 knockout (KO) results in reduced proliferation in 2-D and 3-D cell cultures. RCC1 knockdown (KD) reduced migration and clonogenicity, enhanced apoptosis, and altered cell cycle progression in human PDAC and murine cells from LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx1-Cre (KPC) tumors. Mechanistically, RCC1 KO shows widespread transcriptomic alterations including regulation of PTK7, a co-receptor of the Wnt signaling pathway. RCC1 KD disrupted subcellular Ran localization and the Ran gradient. Nuclear and cytosolic proteomics revealed altered subcellular proteome localization in Rcc1 KD KPC-tumor-derived cells and several altered metabolic biosynthesis pathways. In vivo, RCC1 KO cells show reduced tumor growth potential when injected as sub-cutaneous xenografts. Finally, RCC1 KD sensitized PDAC cells to gemcitabine chemotherapy treatment. This study reveals the role of RCC1 in pancreatic cancer as a novel molecular vulnerability that could be exploited to enhance therapeutic response.
期刊介绍:
Cancer Letters is a reputable international journal that serves as a platform for significant and original contributions in cancer research. The journal welcomes both full-length articles and Mini Reviews in the wide-ranging field of basic and translational oncology. Furthermore, it frequently presents Special Issues that shed light on current and topical areas in cancer research.
Cancer Letters is highly interested in various fundamental aspects that can cater to a diverse readership. These areas include the molecular genetics and cell biology of cancer, radiation biology, molecular pathology, hormones and cancer, viral oncology, metastasis, and chemoprevention. The journal actively focuses on experimental therapeutics, particularly the advancement of targeted therapies for personalized cancer medicine, such as metronomic chemotherapy.
By publishing groundbreaking research and promoting advancements in cancer treatments, Cancer Letters aims to actively contribute to the fight against cancer and the improvement of patient outcomes.